COVID-19与非COVID-19急性呼吸窘迫综合征中丙泊酚相关高甘油三酯血症的比较
这项单中心前瞻性观察性队列研究纳入50例接受持续丙泊酚输注的ARDS患者,其中54%为COVID-19 ARDS。COVID-19组高甘油三酯血症(TG≥500 mg/dL)发生率显著高于非COVID-19组(33.3% vs 4.3%,p=0.014)。COVID-19组发生高甘油三酯血症前接受的丙泊酚累积剂量更高(中位5436.0 mg vs 4229.0 mg,p=0.027)。校正丙泊酚剂量后(OR 5.97,95%CI 1.16-59.57)及倾向评分匹配后(OR 8.64,95%CI 1.27-149.12),COVID-19 ARDS仍与高甘油三酯血症独立相关。两组高甘油三酯血症发生时间无差异(p=0.063),血清脂肪酶无差异(p=0.545),无患者出现胰腺炎症状或体征。
要点
- COVID-19 ARDS患者接受持续丙泊酚输注时,高甘油三酯血症(TG≥500 mg/dL)发生率33.3%,显著高于非COVID-19 ARDS的4.3%(p=0.014)。
- COVID-19组发生高甘油三酯血症前丙泊酚累积剂量中位5436.0 mg,高于非COVID-19组的4229.0 mg(p=0.027)。
- 校正丙泊酚剂量后(OR 5.97,95%CI 1.16-59.57)及倾向评分匹配后(OR 8.64,95%CI 1.27-149.12),COVID-19 ARDS与高甘油三酯血症的关联仍显著。
- 两组高甘油三酯血症发生时间无差异(p=0.063),血清脂肪酶无差异(p=0.545),无患者出现胰腺炎症状或体征。
- 对COVID-19 ARDS患者持续丙泊酚镇静时应警惕高甘油三酯血症,需监测甘油三酯水平。
适用人群与场景
- 2020年4月7日至5月15日收治于内科ICU及区域传染病隔离病房、需要持续丙泊酚输注的ARDS患者,共50例,其中54%为COVID-19 ARDS。
- 排除标准原文未提及。
诊断标准与关键阈值
- 高甘油三酯血症定义为甘油三酯≥500 mg/dL。
- ARDS诊断标准原文未提及。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 基线中位APACHE II评分35.5(IQR 30.2-41),SOFA评分8(IQR 6-9),PaO2/FiO2比值130.5(IQR 94.5-193.8)。
- COVID-19组发生高甘油三酯血症前丙泊酚累积剂量中位5436.0 mg(IQR 3405.5-6845.5),非COVID-19组4229.0 mg(IQR 2083.4-4972.1),p=0.027。
- 校正丙泊酚剂量后的logistic回归OR 5.97(95%CI 1.16-59.57,p=0.031);倾向评分匹配后OR 8.64(95%CI 1.27-149.12,p=0.025)。
- 两组高甘油三酯血症发生时间无差异(p=0.063);发生与未发生高甘油三酯血症者血清脂肪酶无差异(p=0.545);无患者出现胰腺炎症状或体征。
证据类型、等级与局限
- 证据类型:单中心前瞻性观察性队列研究。
- 局限:单中心、样本量小(50例)、观察性设计、未提及盲法、短期观察(2020年4月7日至5月15日)。
对床旁实践的改变
- 对COVID-19 ARDS患者持续输注丙泊酚时,应警惕高甘油三酯血症风险,考虑监测甘油三酯水平。
- COVID-19 ARDS患者发生高甘油三酯血症的风险高于非COVID-19 ARDS患者,即使考虑丙泊酚剂量差异后仍存在。
- 原文未提及是否需要调整丙泊酚剂量或更换镇静药物。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To characterize the incidence and characteristics of propofol-associated hypertriglyceridemia in coronavirus disease 2019 versus noncoronavirus disease 2019 acute respiratory distress syndrome.
DESIGN: Single-center prospective, observational cohort study.
SETTING: Medical ICU and regional infectious containment unit.
PATIENTS: Patients with acute respiratory distress syndrome admitted from April 7, 2020, to May 15, 2020, requiring continuous propofol administration.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Of 50 patients enrolled, 54% had coronavirus disease 2019 acute respiratory distress syndrome. Median Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores were 35.5 (interquartile range, 30.2-41) and 8 (interquartile range, 6-9). Pao2/Fio2 ratio was 130.5 (interquartile range, 94.5-193.8). Patients with coronavirus disease 2019-associated acute respiratory distress syndrome experienced a higher rate of hypertriglyceridemia (triglyceride ≥ 500 mg/dL) than noncoronavirus disease 2019-associated acute respiratory distress syndrome (9 [33.3%] vs 1 [4.3%]; p = 0.014). Those with coronavirus disease 2019, compared with those without, received more propofol prior to becoming hypertriglyceridemic (median, 5,436.0 mg [interquartile range, 3,405.5-6,845.5 mg] vs 4,229.0 mg [interquartile range, 2,083.4-4,972.1 mg]; p = 0.027). After adjustment for propofol dose with logistic regression (odds ratio, 5.97; 95% CI, 1.16-59.57; p = 0.031) and propensity score matching (odds ratio, 8.64; 95% CI, 1.27-149.12; p = 0.025), there remained a significant difference in the development of hypertriglyceridemia between coronavirus disease 2019-associated acute respiratory distress syndrome and noncoronavirus disease 2019-associated acute respiratory distress syndrome. There was no difference between groups in time to hypertriglyceridemia (p = 0.063). Serum lipase was not different between those who did or did not develop hypertriglyceridemia (p = 0.545). No patients experienced signs or symptoms of pancreatitis.
CONCLUSIONS: Patients with coronavirus disease 2019 acute respiratory distress syndrome experienced a higher rate of propofol-associated hypertriglyceridemia than noncoronavirus disease 2019 acute respiratory distress syndrome patients, even after accounting for differences in propofol administration.
参考来源
- Kenes MT, McSparron JI, Marshall VD, et al. Propofol-Associated Hypertriglyceridemia in Coronavirus Disease 2019 Versus Noncoronavirus Disease 2019 Acute Respiratory Distress Syndrome. Crit Care Explor. 2020. PMID: 33354676. doi:10.1097/CCE.0000000000000303
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。